Anjin Angarvi ® (Tsu-mono-injection) approved by the State Drug Administration

osteoblastoma is a histologically benign, but often invasive bone tumor, which occurs in the young and middle age population between the ages of 20 and 40, and the incidence of female sons is slightly higher than that of men, accounting for about 56.4%recently, Anjin China announced that the Angarve ® (English trade name XGEVA ®, generic name: Denosumab Injection) has been approved by the NationalDrug(http://Supervisory Authority for the treatment of non-surgical lycitomas that can lead to severe dysfunction, including adult and bone development (defined as at least 1 mature bone and weight of 45 kg)2018, The Angawi ® was included in the list of clinically urgent lying foreignnew drug(http://(first batch) and entered the Rapid Review Channel of the State Drug AdministrationThe anindication ® was approved based on the results of two open-labeltrial(http://for patients with recurrent, unable to resection or planned surgical removal of osteoblastomas that are likely to cause severe dysfunctionthe latestanalysis of(http://, presented at the 2017 annual meeting of the European Society for Oncology (ESMO), showed that 80 percent of patients who could undergo surgical resection improved after receiving new assisted dissociative recourse: 44 percent underwent surgery with less effect on function and 37 percent avoided surgery in patients who could not be surgically removed, the dysshotonosis led to effective long-term disease control, with a 5-year progression-free survival (PFS) rate of 88%